• Something wrong with this record ?

Small change - big consequence: The impact of C15-C16 double bond in a D‐ring of estrone on estrogen receptor activity

P. Vonka, L. Rarova, V. Bazgier, V. Tichy, T. Kolarova, J. Holcakova, K. Berka, M. Kvasnica, J. Oklestkova, E. Kudova, M. Strnad, R. Hrstka

. 2023 ; 233 (-) : 106365. [pub] 20230717

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Estrogen receptor alpha (ER) is a key biomarker for breast cancer, and the presence or absence of ER in breast and other hormone-dependent cancers decides treatment regimens and patient prognosis. ER is activated after ligand binding - typically by steroid. 2682 steroid compounds were used in a molecular docking study to identify novel ligands for ER and to predict compounds that may show anticancer activity. The effect of the most promising compounds was determined by a novel luciferase reporter assay. Two compounds, 7 and 12, showing ER inhibitory activity comparable to clinical inhibitors such as tamoxifen or fulvestrant were selected. We propose that the inhibitory effect of compounds 7 and 12 on ER is related to the presence of a double bond in their D-ring, which may protect against ER activation by reducing the electron density of the keto group, or may undergo metabolism leading to an active compound. Western blotting revealed that compound 12 decreased the level of ER in the breast cancer cell line MCF7, which was associated with reduced expression of both isoforms of the progesterone receptor, a well-known downstream target of ER. However, compound 12 has a different mechanism of action from fulvestrant. Furthermore, we found that compound 12 interferes with mitochondrial functions, probably by disrupting the electron transport chain, leading to induction of the intrinsic apoptotic pathway even in ER-negative breast cancer cells. In conclusion, the combination of computational and experimental methods shown here represents a rapid approach to determine the activity of compounds towards ER. Our data will not only contribute to research focused on the regulation of ER activity but may also be useful for the further development of novel steroid receptor-targeted drugs applicable in clinical practice.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23016125
003      
CZ-PrNML
005      
20231026110352.0
007      
ta
008      
231013s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jsbmb.2023.106365 $2 doi
035    __
$a (PubMed)37468002
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Vonka, Petr $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic; Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
245    10
$a Small change - big consequence: The impact of C15-C16 double bond in a D‐ring of estrone on estrogen receptor activity / $c P. Vonka, L. Rarova, V. Bazgier, V. Tichy, T. Kolarova, J. Holcakova, K. Berka, M. Kvasnica, J. Oklestkova, E. Kudova, M. Strnad, R. Hrstka
520    9_
$a Estrogen receptor alpha (ER) is a key biomarker for breast cancer, and the presence or absence of ER in breast and other hormone-dependent cancers decides treatment regimens and patient prognosis. ER is activated after ligand binding - typically by steroid. 2682 steroid compounds were used in a molecular docking study to identify novel ligands for ER and to predict compounds that may show anticancer activity. The effect of the most promising compounds was determined by a novel luciferase reporter assay. Two compounds, 7 and 12, showing ER inhibitory activity comparable to clinical inhibitors such as tamoxifen or fulvestrant were selected. We propose that the inhibitory effect of compounds 7 and 12 on ER is related to the presence of a double bond in their D-ring, which may protect against ER activation by reducing the electron density of the keto group, or may undergo metabolism leading to an active compound. Western blotting revealed that compound 12 decreased the level of ER in the breast cancer cell line MCF7, which was associated with reduced expression of both isoforms of the progesterone receptor, a well-known downstream target of ER. However, compound 12 has a different mechanism of action from fulvestrant. Furthermore, we found that compound 12 interferes with mitochondrial functions, probably by disrupting the electron transport chain, leading to induction of the intrinsic apoptotic pathway even in ER-negative breast cancer cells. In conclusion, the combination of computational and experimental methods shown here represents a rapid approach to determine the activity of compounds towards ER. Our data will not only contribute to research focused on the regulation of ER activity but may also be useful for the further development of novel steroid receptor-targeted drugs applicable in clinical practice.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fulvestrant $x farmakologie $x terapeutické užití $7 D000077267
650    12
$a estron $x farmakologie $7 D004970
650    _2
$a receptory pro estrogeny $x metabolismus $7 D011960
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a nádory prsu $x farmakoterapie $x metabolismus $7 D001943
650    _2
$a tamoxifen $x farmakologie $7 D013629
650    _2
$a alfa receptor estrogenů $x genetika $x metabolismus $7 D047628
650    _2
$a estradiol $x farmakologie $x terapeutické užití $7 D004958
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rarova, Lucie $u Department of Experimental Biology, Faculty of Science, Palacký University Olomouc, Šlechtitelů 27, 78371 Olomouc, Czech Republic
700    1_
$a Bazgier, Vaclav $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, třída 17. listopadu 12, 771 46 Olomouc, Czech Republic
700    1_
$a Tichy, Vlastimil $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Kolarova, Tamara $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Holcakova, Jitka $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
700    1_
$a Berka, Karel $u Department of Physical Chemistry, Faculty of Science, Palacký University Olomouc, třída 17. listopadu 12, 771 46 Olomouc, Czech Republic
700    1_
$a Kvasnica, Miroslav $u Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
700    1_
$a Oklestkova, Jana $u Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
700    1_
$a Kudova, Eva $u Institute of Organic Chemistry and Biochemistry AS CR, Flemingovo náměstí 2, 166 10, Praha 6, Czech Republic
700    1_
$a Strnad, Miroslav $u Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic
700    1_
$a Hrstka, Roman $u Research Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic; Laboratory of Growth Regulators, Faculty of Science of Palacký University & Institute of Experimental Botany of the Czech Academy of Sciences, Šlechtitelů 27, 783 71 Olomouc, Czech Republic. Electronic address: hrstka@mou.cz
773    0_
$w MED00004950 $t The Journal of steroid biochemistry and molecular biology $x 1879-1220 $g Roč. 233, č. - (2023), s. 106365
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37468002 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231013 $b ABA008
991    __
$a 20231026110345 $b ABA008
999    __
$a ok $b bmc $g 1999942 $s 1202487
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 233 $c - $d 106365 $e 20230717 $i 1879-1220 $m Journal of steroid biochemistry and molecular biology $n J Steroid Biochem Mol Biol $x MED00004950
LZP    __
$a Pubmed-20231013

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...